Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: a Pediatric Oncology Group pilot study (9139).

Abstract

A phase I Pediatric Oncology Group Study was performed combining 7,020 cGy hyperfractionated irradiation (117 cGy twice daily separated by 6 h) with increasing concurrent doses of cisplatin given with the intent of radiosensitization as treatment for children with newly diagnosed brain stem tumors. Cisplatin was infused over 120 h on weeks 1, 3, and 5 during a 6-week radiotherapy course. The following cisplatin dose levels were studied: (1) 50 mg/m2/120 h, (2) 75 mg/m2/120 h and (3) 100 mg/m2/120 h. Sixteen of 17 children completed therapy. One child expired after 2 days of treatment secondary to massive intratumoral hemorrhage. At cisplatin dose level 3 (100 mg/m2/120 h), grade 2-4 myelosuppression was encountered in 3 of 5 evaluable patients. Otherwise, no other excessive toxicities, including renal and ototoxicity, were noted.

• Authors: R P Kadota, L R Mandell, J Fontanesi, E H Kovnar, J Krischer, L E Kun, H S Friedman
• Journal: Pediatric neurosurgery (Pediatr Neurosurg) Vol. 20 Issue 4 Pg. 221-5 ( 1994) ISSN: 1016-2291 [Print] Switzerland
• PMID: 8043459 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Free Radicals
• Cisplatin

Topics

• Adolescent
• Adult
• Brain Neoplasms (pathology, radiotherapy)
• Brain Stem (pathology, radiation effects)
• Child
• Child, Preschool
• Cisplatin (administration & dosage, adverse effects, therapeutic use)
• Cranial Irradiation
• Dose-Response Relationship, Drug
• Free Radicals
• Hearing Disorders (chemically induced)
• Humans
• Injections, Intravenous
• Pilot Projects
• Prognosis
• Treatment Outcome